A phase III trial of Cyramza (ramucirumab) as a second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of overall survival.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
